
    
      Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been determined,
      up to 10 patients may be enrolled in the cohort-expansion phase to better characterize the
      safety, tolerability and PK of vantictumab combined with nab-paclitaxel and gemcitabine. Up
      to approximately 34 patients may be enrolled into the study.
    
  